NANOPRIMER
LIVE

Serial Number

79291480

Owner

CURADIGM

Attorney

Michele S. Katz

Filing Date

Jun 24, 2020

Add to watchlist:

No watchlists yet
View on USPTO

NANOPRIMER Trademark

Serial Number: 79291480 • Registration: 6422329

NANOPRIMER is a trademark filed by CURADIGM on June 24, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

CURADIGM (2 trademarks)

60 rue de Wattignies

Entity Type: 99

NANOBIOTIX (30 trademarks)

60 rue de Wattignies

Entity Type: 99

Trademark Details

Filing Date

June 24, 2020

Registration Date

July 20, 2021

Published for Opposition

May 4, 2021

Goods & Services

Products for medical use especially for metabolic pathways to prevent and treat acid-base imbalance, metabolic brain diseases, disorders of calcium metabolism, DNA repair-deficiency disorders, glucose metabolism disorders, hyperlactatemia, iron metabolism disorders, lipid metabolism disorders, malabsorption syndromes, metabolic syndrome X, inborn error of metabolism, mitochondrial diseases, phosphorus metabolism disorders, porphyrias, proteostasis deficiencies, metabolic skin diseases, wasting syndrome and water-electrolyte imbalance; products for medical use especially for the diagnosis and treatment of tumors; preparations for medical use especially for modifying the bioavailability of therapeutic agents; preparations for medical use especially for modifying liver functions to prevent and treat alcohol-related liver disease, non-alcoholic fatty liver disease, hepatitis, haemochromatosis, primary biliary cirrhosis and liver cancer; preparations for medical use for modifying the functions of the reticuloendothelial system to decrease reticuloendothelial system ability to trap and metabolize therapeutic agents such as nanomedicines, monoclonal antibodies, antibody-drug conjugates, small molecules, and to prevent and treat Gaucher's disease, mastocytosis, and histiocytosis; preparations based on nanomaterials for the delivery of therapeutic agents combined with nucleic acid, small molecules, proteins and peptides; nanoparticles for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, organ transplant rejection; chemical reagents for medical use; bacteriological preparations for medical use; biological preparations for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, organ transplant rejection; enzymes for medical use; enzyme preparations for medical use; diagnostic products for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; drugs for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; medicines for human to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; tonics for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; antibiotics; antiseptics; chemico-pharmaceutical preparations for the treatment of central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; pharmaceutical preparations for the treatment of central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; dietetic substances preparations adapted for medical use; remedies for human medicine for the treatment of central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection

Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy

Scientific and technological services as well as, namely, research and design services particularly in the field of nanomedicine which is nanotechnology applied to medicine; biological research; research in bacteriology; conducting early evaluations in the field of new pharmaceuticals; design and development of new products for third parties; conducting clinical trials for others in the field of new pharmaceuticals; research services in the field of new pharmaceuticals; chemical analysis; chemical research; chemical engineering; chemical research and analysis services in the field of physico-chemical characterization and concept design; engineering work, namely, surveying; research and development of new products for third parties; technical research in the field of new pharmaceuticals; radiobiology research; research in nanoscience and nanotechnology, especially applied to medicine

Filing History

CHANGE OF OWNER RECEIVED FROM IB
Dec 27, 2024 CHLD
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 13, 2021 FINO
CHANGE OF NAME/ADDRESS REC'D FROM IB
Dec 4, 2021 ADCH
FINAL DISPOSITION NOTICE SENT TO IB
Nov 17, 2021 FICS
FINAL DISPOSITION PROCESSED
Nov 17, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 20, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 20, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 4, 2021 NPUB
PUBLISHED FOR OPPOSITION
May 4, 2021 PUBO
NOTIFICATION PROCESSED BY IB
May 2, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 14, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 14, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 14, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 26, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 26, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 26, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 26, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 26, 2021 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Mar 26, 2021 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 26, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 19, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 18, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 18, 2021 TROA
REFUSAL PROCESSED BY IB
Nov 29, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 6, 2020 RFCS
REFUSAL PROCESSED BY MPU
Nov 5, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 18, 2020 RFCR
NON-FINAL ACTION WRITTEN
Oct 17, 2020 CNRT
ASSIGNED TO EXAMINER
Sep 27, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 18, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 14, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 13, 2020 REPR